Cryoport Systems

Congratulations to our client, Mesoblast Limited ($MESO), on their FDA approval of RYONCIL®, the first mesenchymal stromal cell therapy approved in the United States! This groundbreaking therapy represents a significant milestone for children with steroid-refractory acute graft-versus-host disease (SR-aGvHD). At Cryoport Systems, we’re proud to support Mesoblast by Enabling the Outcome through our safe, secure, and compliant temperature-controlled supply chain solutions. Together, we’re advancing the future of cell-based medicine and delivering hope to patients and families worldwide. $CYRX #CellTherapy #FDAApproval #CryoportSystems #TemperatureControlledLogistics #EnablingTheOutcome

For gene therapies, any fluctuations in temperature or physical handling can compromise the therapy’s effectiveness and, by extension, patient safety. The development of the custom-engineered payload holding system in the Cryoport Elite® Ultra Cold shipping system offers a solution by isolating the payload away from making direct contact with dry ice, providing an even temperature distribution while securing the packaging. Learn More: https://lnkd.in/g6KUruPQ

For many, the most challenging aspect of storing and shipping #BiologicalMaterials is the maintenance of the chain of condition and chain of custody. Ensuring a fragile shipment is facilitated appropriately requires the #ChainofCompliance, an established process used in managing environmental control of the shipped commodity. Read the Chain of Compliance™ #WhitePaper to understand why traceability is essential and the steps companies should take now to ensure future compliance: https://cyrx.co/3z83fQ5 #EnablingTheOutcome $CYRX

How do you ensure the seamless flow of materials in a cell and gene therapy supply chain? From variability in starting materials to the challenges of therapy delivery, our experts offer strategies to help you break through bottlenecks.   Access the on-demand webinar now and learn how to optimize your supply chain for better outcomes: https://lnkd.in/gtyG6yM5

The high stakes of gene therapy, where each shipment can represent years of research and millions of dollars in investment, demand logistics solutions that can handle the unique challenges posed by temperature sensitivity, transit stability, and security. We developed the Cryoport Elite® Ultra Cold shipping system with one mission in mind: to ensure that gene therapies reach their destination intact, uncompromised, and ready for patient treatment. Learn More: https://lnkd.in/g6KUruPQ

Trust Cryoport Systems to deliver your cell & gene therapies safely and efficiently with the #CryoportElite™ Ultra Cold -60 to -80°C dry ice shipper. Our commitment to your #SupplyChainSuccess provides peace of mind knowing your high-value commodities are in expert hands. $CYRX Learn More: https://cyrx.co/3JePD7m

Gene therapy logistics demand more than traditional solutions. Hear from Cryoport Systems Senior Vice President, Mike Dybicz, and Director of Product Marketing, Khoa Tran as they discuss how we're meeting the gene therapy industry's most pressing needs and helping to deliver life-changing therapies. https://lnkd.in/gN6xnU4N

Revolutionize your gene therapy supply chain. Our supply chain management platform of solutions – which includes biostorage, ultra-cold shipping systems, logistics and consulting – ensures your materials are in safe hands. We are purpose-built to mitigate risk for researchers, developers, and manufacturers. https://cyrx.co/3Ve8uVW #GeneTherapy #MitigateRisk #SupplyChainExcellence $CYRX

Our #SupplyChain and logistics solutions encompass capabilities that support intelligent data flow and continuous traceability and management for every stage, phase, and commodity type. $CYRX Learn more: https://cyrx.co/3KQE8E7 #EnableTheOutcome

Scaling cell therapies from clinical to commercial stages requires overcoming complex logistical and material standardization hurdles. Attend tomorrow's webinar, "Preserving the Future of Medicine: Standardizing Leukapheresis Materials with Cryopreservation for Scalable Cell Therapies," to gain actionable insights on: * Minimizing variability in starting materials * Streamlining site qualification and logistics * Optimizing end-to-end supply chain solutions There's still time to register! Reserve your seat today: https://lnkd.in/gZ--vT7c